SUPNSupernus Pharmaceuticals, Inc.

$3B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$168M+24.2% YoY

Gross Profit

$150M89.4% margin

Operating Income

$23M13.4% margin

Net Income

$20M11.8% margin

EPS (Diluted)

$0.36

QoQ Revenue Growth

+17.2%

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$36M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$358M

Stockholders' Equity

$957M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$168M	$136M	+24.2%
Gross Profit	$150M	$114M	+31.4%
Operating Income	$23M	-$18M	+228.3%
Net Income	$20M	-$831,000	+2496.6%

Revenue Segments

Product

$163M49%

Qelbree

$59M18%

GOCOVRI

$32M10%

Oxtellar X R

$30M9%

APOKYN

$17M5%

Trokendi Xr

$17M5%

Manufactured Product, Other

$8M2%

Royalty, License And Other Revenue

$6M2%

SUPN Q2 2024 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena